Ann McNeill
Oncology · Neptune, NJNPI 1396973897
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $250,052 of the $371,858 with a category attached, or 67.2%. It is spread thinly across 29 manufacturers, the largest accounting for just 19.5%. Reporting peaked in 2022 at $117,110 and has fallen 65.0% since, to $41,017 in 2025. Among oncology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 693 payments — averaging $536.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$73K
- Seagen Inc.$69K
- Pharmacyclics LLC, An Abbvie Company$61K
- Amgen$54K
- E.r. Squibb & Sons, L.L.C.$36K
- Karyopharm Therapeutics Inc.$31K
- plus $48K from 23 others
What the payments were for
- Consulting fees$3,9351%
- Speaking & faculty fees$250,05267%
- Grants$5000%
- Travel & lodging$99,65727%
- Food & beverage$17,2505%
- Education$4650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 98 | $72,670 |
| Seagen Inc. | 134 | $68,870 |
| Pharmacyclics LLC, An Abbvie Company | 88 | $61,355 |
| Amgen | 92 | $53,896 |
| E.r. Squibb & Sons, L.L.C. | 72 | $35,959 |
| Karyopharm Therapeutics Inc. | 52 | $31,181 |
| Johnson & Johnson | 46 | $22,239 |
| Incyte Corporation | 31 | $14,430 |
| Bristol Myers Squibb | 16 | $5,349 |
| Sanofi | 12 | $4,299 |
| AbbVie | 7 | $364 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $171 |
| Genentech USA, Inc. | 2 | $166 |
| Daiichi Sankyo Inc. | 2 | $152 |
| Sanofi-aventis U.S. LLC | 4 | $126 |
| Legend Biotech USA Inc. | 1 | $100 |
| Taiho Oncology, Inc. | 6 | $98 |
| Adaptive Biotechnologies Corporation | 2 | $69 |
| Novartis | 2 | $61 |
| Astellas Pharma US Inc | 3 | $58 |
| AstraZeneca | 3 | $44 |
| Janssen Scientific Affairs, LLC | 1 | $43 |
| Merck | 2 | $36 |
| Acrotech Biopharma Inc. | 2 | $29 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| CTI Biopharma Corp. | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$371,858 in reported general payments places this provider in the 95th percentile of 23 oncology providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 19 | $253 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 49 | $139 |
| Pantoprazole Sodium | 11 | $68 |
Paid to pharmacies, not to this prescriber.
Other oncology in Neptune
- Susan WilsonMarmora$10K
- Carol BlecherElizabeth$6K
- Wendy VogelLawrenceville$3K
- Deborah SmithRiverdale$2K
- Michelyne GavinCliffside Park$2K
- Amber DelecceSewell$1K
- Jacquelynn WhiteCamden$908
- Mary KellyBerkeley Heights$799
- Dina EspositoWest Orange$620
- Carol BoyerBerkeley Heights$482
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.